Stock Watch: Are Gene Therapy Prices Too High For Success?
Pfizer Bows Out, Who Will Be Next?
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
